Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R; Lungscape Consortium.

Lung Cancer. 2019 May;131:95-103. doi: 10.1016/j.lungcan.2019.03.012. Epub 2019 Mar 15.

PMID:
31027705
2.

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S.

J Thorac Oncol. 2019 Jun;14(6):1086-1094. doi: 10.1016/j.jtho.2019.02.017. Epub 2019 Feb 27.

PMID:
30825613
3.

Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples.

O'Brien O, Wright MC, O'Brien C, Geoghegan O, Leonard N, Nicholson S, Cuffe S, Fabre A, Jochum W, Joerger M, Gray SG, Finn SP.

Diagnostics (Basel). 2019 Jan 18;9(1). pii: E13. doi: 10.3390/diagnostics9010013.

4.

A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.

Pernar CH, Ebot EM, Pettersson A, Graff RE, Giunchi F, Ahearn TU, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Stopsack KH, Gazeeva E, Lis RT, Parmigiani G, Rimm EB, Finn SP, Giovannucci EL, Fiorentino M, Mucci LA.

Eur Urol. 2019 Jul;76(1):33-40. doi: 10.1016/j.eururo.2018.09.041. Epub 2018 Oct 6.

PMID:
30301696
5.

Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.

Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A.

J Thorac Oncol. 2018 Dec;13(12):1851-1863. doi: 10.1016/j.jtho.2018.08.2034. Epub 2018 Sep 18.

6.

RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer-From Cell Line Models to Liquid Biopsies.

Lim MCJ, Baird AM, Aird J, Greene J, Kapoor D, Gray SG, McDermott R, Finn SP.

Diagnostics (Basel). 2018 Aug 30;8(3). pii: E60. doi: 10.3390/diagnostics8030060. Review.

7.

Carcinogenesis in prostate cancer: The role of long non-coding RNAs.

Aird J, Baird AM, Lim MCJ, McDermott R, Finn SP, Gray SG.

Noncoding RNA Res. 2018 Feb 1;3(1):29-38. doi: 10.1016/j.ncrna.2018.01.001. eCollection 2018 Mar. Review.

8.

Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.

Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvão DA, Ryan CJ, Saad F.

BMJ Open. 2018 May 14;8(5):e022899. doi: 10.1136/bmjopen-2018-022899.

9.

BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC.

MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP.

Cancer Lett. 2018 Aug 1;428:117-126. doi: 10.1016/j.canlet.2018.04.008. Epub 2018 Apr 11.

PMID:
29653268
10.

Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.

Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K.

Sci Rep. 2018 Jan 26;8(1):1652. doi: 10.1038/s41598-018-19688-1.

11.

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.

MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Breen E, Gray SG, Nicholson S, Leonard N, Ryan R, Young V, O'Leary JJ, Cuffe S, Finn SP, O'Byrne KJ, Barr MP.

Oncotarget. 2017 Aug 3;8(42):72544-72563. doi: 10.18632/oncotarget.19881. eCollection 2017 Sep 22.

12.

Expression of protein kinase C gamma promotes cell migration in colon cancer.

Dowling CM, Hayes SL, Phelan JJ, Cathcart MC, Finn SP, Mehigan B, McCormick P, Coffey JC, O'sullivan J, Kiely PA.

Oncotarget. 2017 Jul 1;8(42):72096-72107. doi: 10.18632/oncotarget.18916. eCollection 2017 Sep 22.

13.

Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin-αv trafficking.

Prichard DO, Byrne AM, Murphy JO, Reynolds JV, O'Sullivan J, Feighery R, Doyle B, Eldin OS, Finn SP, Maguire A, Duff D, Kelleher DP, Long A.

J Cell Mol Med. 2017 Dec;21(12):3612-3625. doi: 10.1111/jcmm.13271. Epub 2017 Sep 22.

14.

Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer.

Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, Bondi A, Lis R, Van Hemelrijck M, Andrén O, Andersson SO, Watson RW, Pennington S, Finn SP, Martin NE, Stampfer MJ, Parmigiani G, Penney KL, Fiorentino M, Mucci LA, Loda M.

Nat Commun. 2017 Sep 4;8(1):420. doi: 10.1038/s41467-017-00460-4.

15.

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.

Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA; Lungscape Consortium.

Lung Cancer. 2017 Sep;111:143-149. doi: 10.1016/j.lungcan.2017.07.021. Epub 2017 Jul 22.

PMID:
28838386
16.

Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.

Breen KJ, O'Neill A, Murphy L, Fan Y, Boyce S, Fitzgerald N, Dorris E, Brady L, Finn SP, Hayes BD, Treacy A, Barrett C, Aziz MA, Kay EW, Fitzpatrick JM, Watson RWG.

Prostate. 2017 Sep;77(12):1288-1300. doi: 10.1002/pros.23389. Epub 2017 Jul 20.

PMID:
28726241
17.

Circular RNAs: Biogenesis, Function and Role in Human Diseases.

Greene J, Baird AM, Brady L, Lim M, Gray SG, McDermott R, Finn SP.

Front Mol Biosci. 2017 Jun 6;4:38. doi: 10.3389/fmolb.2017.00038. eCollection 2017. Review.

18.

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells.

Heery R, Finn SP, Cuffe S, Gray SG.

Cancers (Basel). 2017 Apr 21;9(4). pii: E38. doi: 10.3390/cancers9040038. Review.

19.

Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.

Cregan S, Breslin M, Roche G, Wennstedt S, MacDonagh L, Albadri C, Gao Y, O'Byrne KJ, Cuffe S, Finn SP, Gray SG.

Int J Oncol. 2017 Mar;50(3):1044-1052. doi: 10.3892/ijo.2017.3870. Epub 2017 Feb 9.

PMID:
28197626
20.

Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment.

Staunton L, Tonry C, Lis R, Espina V, Liotta L, Inzitari R, Bowden M, Fabre A, O'Leary J, Finn SP, Loda M, Pennington SR.

Mol Cancer Res. 2017 Mar;15(3):281-293. doi: 10.1158/1541-7786.MCR-16-0358. Epub 2017 Jan 5.

21.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?

Gray SG, Cuffe S, Finn SP.

J Thorac Oncol. 2016 Nov;11(11):e142-e144. doi: 10.1016/j.jtho.2016.07.025. No abstract available.

22.

The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer.

Tonry CL, Leacy E, Raso C, Finn SP, Armstrong J, Pennington SR.

Diagnostics (Basel). 2016 Jul 18;6(3). pii: E27. doi: 10.3390/diagnostics6030027. Review.

23.

Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification.

Hayes BD, Brady L, Pollak M, Finn SP.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1281-8. doi: 10.1158/1055-9965.EPI-16-0223. Epub 2016 Jul 7. Review.

24.

The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

Joerger M, Finn SP, Cuffe S, Byrne AT, Gray SG.

Expert Opin Ther Targets. 2016 Nov;20(11):1339-1356. Epub 2016 Jul 11. Review.

PMID:
27353429
25.

Lung cancer stem cells: The root of resistance.

MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP.

Cancer Lett. 2016 Mar 28;372(2):147-56. doi: 10.1016/j.canlet.2016.01.012. Epub 2016 Jan 18. Review.

PMID:
26797015
26.

Non-coding RNA repertoires in malignant pleural mesothelioma.

Quinn L, Finn SP, Cuffe S, Gray SG.

Lung Cancer. 2015 Dec;90(3):417-26. doi: 10.1016/j.lungcan.2015.11.002. Epub 2015 Nov 10. Review.

PMID:
26791801
27.

KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.

Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG.

Int J Oncol. 2016 Mar;48(3):1290-6. doi: 10.3892/ijo.2016.3335. Epub 2016 Jan 13.

PMID:
26780987
28.

Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.

Leon G, MacDonagh L, Finn SP, Cuffe S, Barr MP.

Pharmacol Ther. 2016 Feb;158:71-90. doi: 10.1016/j.pharmthera.2015.12.001. Epub 2015 Dec 17. Review.

PMID:
26706243
29.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149.

PMID:
25746038
30.

The emerging role of microRNAs in resistance to lung cancer treatments.

MacDonagh L, Gray SG, Finn SP, Cuffe S, O'Byrne KJ, Barr MP.

Cancer Treat Rev. 2015 Feb;41(2):160-9. doi: 10.1016/j.ctrv.2014.12.009. Epub 2014 Dec 23. Review.

PMID:
25592062
31.

Enzalutamide for treatment of CRPC: rationale for sequencing and potential clinical biomarker for resistance.

Lochrin SE, Figg WD 2nd, Finn SP.

Cancer Biol Ther. 2015;16(2):201-3. doi: 10.4161/15384047.2014.987575.

32.

The role of DNA repair pathways in cisplatin resistant lung cancer.

O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP.

Cancer Treat Rev. 2014 Dec;40(10):1161-70. doi: 10.1016/j.ctrv.2014.10.003. Epub 2014 Oct 18. Review.

PMID:
25458603
33.

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.

Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K.

Cancer Biol Ther. 2014 Oct;15(10):1367-77. doi: 10.4161/cbt.29841. Epub 2014 Jul 15.

34.

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.

Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3.

35.

Molecular testing in oncology: problems, pitfalls and progress.

O'Brien CP, Taylor SE, O'Leary JJ, Finn SP.

Lung Cancer. 2014 Mar;83(3):309-15. doi: 10.1016/j.lungcan.2013.12.010. Epub 2014 Jan 3. Review.

PMID:
24472389
36.

Application of statistical process control to qualitative molecular diagnostic assays.

O'Brien CP, Finn SP.

Front Mol Biosci. 2014 Nov 5;1:18. doi: 10.3389/fmolb.2014.00018. eCollection 2014.

37.

Predictive values for molecular diagnostics: converting unknown unknowns to known unknowns.

O'Brien CP, Langabeer SE, O'Byrne KJ, O'Leary JJ, Finn SP.

Mol Diagn Ther. 2014 Feb;18(1):1-4. doi: 10.1007/s40291-013-0076-x. No abstract available.

PMID:
24338436
38.

Kidney volume correlates with tumor diameter in renal cell carcinoma and is associated with histological poor prognostic features.

Hayes BD, Finn SP.

Int J Surg Pathol. 2014 Feb;22(1):39-46. doi: 10.1177/1066896913511525. Epub 2013 Dec 5.

PMID:
24319047
39.

Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.

Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2354-63. doi: 10.1158/1055-9965.EPI-13-0668. Epub 2013 Oct 15.

40.

IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity.

Doyle SL, Donohoe CL, Finn SP, Howard JM, Lithander FE, Reynolds JV, Pidgeon GP, Lysaght J.

Am J Gastroenterol. 2012 Feb;107(2):196-204. doi: 10.1038/ajg.2011.417. Epub 2011 Dec 6.

PMID:
22146489
41.

RET protein expression in papillary renal cell carcinoma.

Flavin R, Finn SP, Choueiri TK, Ingoldsby H, Ring M, Barrett C, Rogers M, Smyth P, O'Regan E, Gaffney E, O'Leary JJ, Loda M, Signoretti S, Sheils O.

Urol Oncol. 2012 Nov-Dec;30(6):900-5. doi: 10.1016/j.urolonc.2010.08.025. Epub 2011 Mar 10.

PMID:
21396847
42.

miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma.

Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J, Laios A, O'Toole S, Ring M, Denning K, Li J, Aherne S, Sammarae D, Aziz NA, Alhadi A, Finn SP, Loda M, B S, Sheils O, O'Leary JJ.

Int J Gynecol Cancer. 2009 May;19(4):641-7. doi: 10.1111/IGC.0b013e3181a48cf9.

PMID:
19509563
43.

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.

Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA, Kung AL, Golub TR.

Nat Biotechnol. 2009 Jan;27(1):77-83. doi: 10.1038/nbt.1513. Epub 2008 Dec 21.

44.

Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma.

Flavin RJ, Smyth PC, Laios A, O'Toole SA, Barrett C, Finn SP, Russell S, Ring M, Denning KM, Li J, Aherne ST, Sammarae DA, Aziz NA, Alhadi A, Sheppard BL, Lao K, Sheils OM, O'Leary JJ.

Mod Pathol. 2009 Feb;22(2):197-205. doi: 10.1038/modpathol.2008.135. Epub 2008 Aug 1.

45.

Potential role of miR-9 and miR-223 in recurrent ovarian cancer.

Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B, O' Leary J.

Mol Cancer. 2008 Apr 28;7:35. doi: 10.1186/1476-4598-7-35.

46.

Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients.

Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, Aziz NA, Alhadi A, Sheppard BL, Loda M, Martin C, Sheils OM, O'Leary JJ.

Mod Pathol. 2008 Jun;21(6):676-84. doi: 10.1038/modpathol.2008.33. Epub 2008 Mar 7.

47.

p16(INK4A) genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas.

O'Regan EM, Toner ME, Finn SP, Fan CY, Ring M, Hagmar B, Timon C, Smyth P, Cahill S, Flavin R, Sheils OM, O'Leary JJ.

Hum Pathol. 2008 Mar;39(3):452-8. doi: 10.1016/j.humpath.2007.08.004.

PMID:
18261630
48.

Surgical feasibility study of a novel polytetrafluoroethylene graft design for the treatment of peripheral arterial disease.

O'Brien TP, Walsh MT, Kavanagh EG, Finn SP, Grace PA, McGloughlin TM.

Ann Vasc Surg. 2007 Sep;21(5):611-7.

PMID:
17823043
49.

A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples.

Denning KM, Smyth PC, Cahill SF, Finn SP, Conlon E, Li J, Flavin RJ, Aherne ST, Guenther SM, Ferlinz A, O'Leary JJ, Sheils OM.

Mod Pathol. 2007 Oct;20(10):1095-102. Epub 2007 Jul 27.

50.

Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.

Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL.

Cancer Cell. 2007 Jun;11(6):555-69.

Supplemental Content

Support Center